



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Richard G. Olsen, *et al.*)
Serial No. 09/125,841) Examiner Ronald B. Schwadron, Ph.D.
Filed: January 19, 1999) Group Art Unit 1644
For: Cellular Immunotherapy)

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

TECH CENTER 1600/2900

APR 16 2003

RECEIVED

**RESPONSE TO NOTICE OF SEQUENCE LISTING REQUIREMENTS
AND AMENDMENT**

Sir:

Responsive to the outstanding Office communication mailed on December 18, 2002 (paper unidentified), Applicants submit herewith a properly formatted computer-readable copy of a Sequence Listing pursuant to 37 C.F.R. § 1.821, *et seq.*, along with a paper copy to be added to the specification. Two identical compact disks are herewith submitted, labeled "Copy 1" and "Copy 2." The below-signed attorney hereby attests to the fact that the "Sequence Listing" on the enclosed compact disks as submitted herewith are identical to the paper copy of the "Sequence Listing" added to the specification by amendment herein, pursuant to 37 C.F.R. § 1.821(f). The "Sequence Listing" on the enclosed compact disks is contained in the file named "CIR2-001-3 #4.prj" and was created by PatentIn version 3.1 software and burned onto the compact disk on a macintosh computer.

By his signature below, the undersigned attests to the fact that no new matter is introduced into the specification by these amendments or this computer-readable copy of the instant Sequence Listing.

REMARKS

The replacement page submitted herewith comprises a Sequence Listing pursuant to 37 C.F.R. § 1.821 *et seq.* The amendments to the specification are made to identify the species origin of the nucleotide sequences identified as SEQ ID Nos. 1-4 in the Sequence Listing in compliance with 37 C.F.R. §1.823.

In our previous submission of September 23, 2002, the following remarks were included to explain changes in the sequence submission. As the computer readable format of the